S14 Ep11: Breaking Down the Rationale for Targeting TROP2 in TNBC
In this podcast, experts Filipa Lynce, MD, and Rita Nanda, MD, discuss unmet needs in triple-negative breast cancer (TNBC) and the rationale for using TROP2-targeting antibody-drug conjugates (ADCs) in this disease.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.